Abbott Laboratories Plans Quarterly Dividend of $0.63 (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) announced a quarterly dividend on Thursday, September 17th. Shareholders of record on Thursday, October 15th will be given a dividend of 0.63 per share by the healthcare product maker on Monday, November 16th. This represents a c) annualized dividend and a yield of 2.5%. The ex-dividend date is Thursday, October 15th.

Abbott Laboratories has raised its dividend by an average of 0.1%annually over the last three years and has increased its dividend every year for the last 54 years. Abbott Laboratories has a payout ratio of 44.4% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Abbott Laboratories to earn $6.08 per share next year, which means the company should continue to be able to cover its $2.52 annual dividend with an expected future payout ratio of 41.4%.

Abbott Laboratories Trading Down 0.2%

ABT stock opened at $102.20 on Friday. The company has a market cap of $176.84 billion, a price-to-earnings ratio of 33.07, a PEG ratio of 1.90 and a beta of 0.59. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The business has a fifty day simple moving average of $106.18 and a 200-day simple moving average of $99.38. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same quarter in the previous year, the business posted $1.26 EPS. The business’s quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities research analysts expect that Abbott Laboratories will post 5.52 EPS for the current year.

Hedge Funds Weigh In On Abbott Laboratories

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Menlo Advisors LLC boosted its holdings in shares of Abbott Laboratories by 1.1% in the second quarter. Menlo Advisors LLC now owns 67,919 shares of the healthcare product maker’s stock worth $6,162,000 after buying an additional 723 shares during the period. Core Capital Management & Research inc. purchased a new stake in Abbott Laboratories in the 2nd quarter worth about $64,000. The Manufacturers Life Insurance Company increased its holdings in shares of Abbott Laboratories by 5.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,370,397 shares of the healthcare product maker’s stock valued at $487,310,000 after purchasing an additional 254,205 shares during the period. Capstone Financial Advisors Inc. increased its stake in Abbott Laboratories by 10.6% in the 2nd quarter. Capstone Financial Advisors Inc. now owns 3,300 shares of the healthcare product maker’s stock valued at $299,000 after buying an additional 316 shares during the period. Finally, Archford Capital Strategies LLC increased its stake in shares of Abbott Laboratories by 17.2% in the second quarter. Archford Capital Strategies LLC now owns 2,715 shares of the healthcare product maker’s stock worth $246,000 after acquiring an additional 398 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.